Dyax sells Xyntha royalty stream to Paul Capital
This article was originally published in Scrip
Executive Summary
Dyax has sold its rights to royalties and other payments related to the commercialisation of Xyntha/ReFacto AF (moroctocog alfa) by Pfizer, one of many licenseesof Dyax's phage display libraries, to Paul Capital Healthcare.